An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry

被引:108
作者
Velazquez, EJ
Francis, GS
Armstrong, PW
Aylward, PE
Diaz, R
O'Connor, CM
White, HD
Henis, M
Rittenhouse, LM
Kilaru, R
van Gilst, W
Ertl, G
Maggioni, AP
Spac, J
Weaver, WD
Rouleau, JL
McMurray, JJV
Pfeffer, MA
Califf, RM
机构
[1] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27715 USA
[2] Duke Clin Res Inst, Durham, NC 27715 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Univ Alberta, Edmonton, AB, Canada
[5] Flinders Med Ctr, Bedford Pk, SA, Australia
[6] Estudios Cardiol, Santa Fe, Argentina
[7] Green Lane Hosp, Auckland 3, New Zealand
[8] Med Pharmaceut Consultants, Randolph, NJ USA
[9] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[10] Univ Wurzburg, Med Klin, Wurzburg, Germany
[11] ANMCO Res Ctr, Florence, Italy
[12] Fac Hosp St Anna, Brno, Czech Republic
[13] Henry Ford Hosp, Detroit, MI 48202 USA
[14] Univ Toronto, Toronto, ON, Canada
[15] Univ Glasgow, Glasgow, Lanark, Scotland
[16] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
heart failure; myocardial infarction; prognosis; left ventricular dysfunction; Killip class;
D O I
10.1016/j.ehj.2004.08.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims We analysed the contemporary incidence, outcomes, and predictors of heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) before discharge in patients with acute myocardial infarction (MI). The baseline presence of HF or LVSD, or its development during hospitalisation, increases short- and long-term risk after MI, yet its incidence, predictors, and outcomes have not been well described in a large, international, general. MI population. Methods and results The VALIANT registry included 5573 consecutive MI patients at 84 hospitals in nine countries from 1999 to 2001. A multivariable logistic survival model was constructed using baseline variables to determine the adjusted mortality risk for those with in-hospital HF and/or LVSD. Baseline variables were also tested for associations with in-hospital HF and/or LVSD. Of the 5566 patients analysed, 42% had HF and/or LVSD during hospitalisation. Their in-hospital. mortality rate was 13.0% compared with 2.3% for those without HF and/or without LVSD. After adjustment for other baseline risk factors, in-hospital HF and/or LVSD carried a hazard ratio for inhospital mortality of 4.12 (95% confidence interval: 3.08-5.56). Patients with HF and/or LVSD also had disproportionately higher rates of other cardiovascular events. Conclusions HF and/or LVSD is common in the general contemporary MI population and precedes 80.3% of all in-hospital deaths after MI. Survivors of early MI-associated HF and/or LVSD have more complications, Longer hospitalisations, and are more likely to die during hospitalisation. Although baseline variables can identify MI patients at highest risk for HF and/or LVSD, such patients are less likely to receive indicated procedures and medical therapies. (C) 2004 The European Society of Cardiology. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1911 / 1919
页数:9
相关论文
共 41 条
  • [1] *AIRE STUD INV EFF, 1993, LANCET, V342, P8218
  • [2] Clinical predictors of heart failure in patients with first acute myocardial infarction
    Ali, AS
    Rybicki, BA
    Alam, M
    Wulbrecht, N
    Richer-Cornish, K
    Khaja, F
    Sabbah, HN
    Goldstein, S
    [J]. AMERICAN HEART JOURNAL, 1999, 138 (06) : 1133 - 1139
  • [3] Myocardial infarction redefined -: A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction
    Alpert, JS
    Antman, E
    Apple, F
    Armstrong, PW
    Bassand, JP
    de Luna, AB
    Beller, G
    Breithardt, G
    Chaitman, BR
    Clemmensen, P
    Falk, E
    Fishbein, MC
    Galvani, M
    Garson, A
    Grines, C
    Hamm, C
    Hoppe, U
    Jaffe, A
    Katus, H
    Kjekshus, J
    Klein, W
    Klootwijk, P
    Lenfant, C
    Levy, D
    Levy, RI
    Luepker, R
    Marcus, F
    Näslund, U
    Ohman, M
    Pahlm, O
    Poole-Wilson, P
    Popp, R
    Pyörälä, K
    Ravkilde, J
    Rehnquist, N
    Roberts, W
    Roberts, R
    Roelandt, J
    Rydén, L
    Sans, S
    Simoons, ML
    Thygesen, K
    Tunstall-Pedoe, H
    Underwood, R
    Uretsky, BF
    de Werf, FV
    Voipio-Pulkki, LM
    Wagner, G
    Wallentin, L
    Wijns, W
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 (18) : 1502 - 1513
  • [4] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
    ALTMAN, R
    CARRERAS, L
    DIAZ, R
    FIGUEROA, E
    PAOLASSO, E
    PARODI, JC
    CADE, JF
    DONNAN, G
    EADIE, MJ
    GAVAGHAN, TP
    OSULLIVAN, EF
    PARKIN, D
    RENNY, JTG
    SILAGY, C
    VINAZZER, H
    ZEKERT, F
    ADRIAENSEN, H
    BERTRANDHARDY, JM
    BRAN, M
    DAVID, JL
    DRICOT, J
    LAVENNEPARDONGE, E
    LIMET, R
    LOWENTHAL, A
    MORIAU, M
    SCHAPIRA, S
    SMETS, P
    SYMOENS, J
    VERHAEGHE, R
    VERSTRAETE, M
    ATALLAH, A
    BARNETT, H
    BATISTA, R
    BLAKELY, J
    CAIRNS, JA
    COTE, R
    CROUCH, J
    EVANS, G
    FINDLAY, JM
    GENT, M
    LANGLOIS, Y
    LECLERC, J
    NORRIS, J
    PINEO, GF
    POWERS, PJ
    ROBERTS, R
    SCHWARTZ, L
    SICURELLA, J
    TAYLOR, W
    THEROUX, P
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921): : 81 - 100
  • [5] [Anonymous], 1994, BMJ, V308, P81, DOI [10.1136/bmj.308.6921.81, DOI 10.1136/BMJ.308.6921.81]
  • [6] INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS
    APPLEBY, P
    BAIGENT, C
    COLLINS, R
    FLATHER, M
    PARISH, S
    PETO, R
    BELL, P
    HALLS, H
    MEAD, G
    DIAZ, R
    PAOLASSO, E
    PAVIOTTI, C
    ROMERO, G
    CAMPBELL, T
    OROURKE, MF
    THOMPSON, P
    LESAFFRE, E
    VANDEWERF, F
    VERSTRAETE, M
    ARMSTRONG, PW
    CAIRNS, JA
    MORAN, C
    TURPIE, AG
    YUSUF, S
    GRANDE, P
    HEIKKILA, J
    KALA, R
    BASSAND, JP
    BOISSEL, JP
    BROCHIER, M
    LEIZOROVICZ, A
    BRUGGEMANN, T
    KARSCH, KR
    KASPER, W
    LAMMERTS, D
    NEUHAUS, KL
    MEYER, J
    SCHRODER, R
    VONESSEN, R
    SARAN, RK
    ARDISSINO, D
    BONADUCE, D
    BRUNELLI, C
    CERNIGLIARO, C
    FORESTI, A
    FRANZOSI, MG
    GUIDUCCI, D
    MAGGIONI, A
    MAGNANI, B
    MATTIOLI, G
    [J]. LANCET, 1994, 343 (8893) : 311 - 322
  • [7] Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the united states: Data from the National Registry of Myocardial Infarction 2
    Barron, HV
    Michaels, AD
    Maynard, C
    Every, NR
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (02) : 360 - 367
  • [8] BRAUNWALD E, 2002, ACC AHA 2002 GUIDELI
  • [9] *CURE TRIAL INV, 2001, NEW ENGL J MED, V345, P1506
  • [10] Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial
    Dargie, HJ
    Colucci, Y
    Ford, I
    Sendon, JLL
    Remme, W
    Sharpe, N
    Blank, A
    Holcslaw, TL
    [J]. LANCET, 2001, 357 (9266) : 1385 - 1390